{"classes":[{"categories":[{"measurements":[{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG000","spread":"NA","value":"497"},{"groupId":"OG001","spread":"657","value":"632"},{"groupId":"OG002","spread":"435","value":"697"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 1 day 1, 1 - 2.5 hours post EOI"},{"categories":[{"measurements":[{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG000","spread":"NA","value":"299"},{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG001","spread":"NA","value":"15.8"},{"groupId":"OG002","spread":"48.9","value":"78.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 1 day 1, 2.75 - 5 hours post EOI"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","spread":"285","value":"142"},{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG002","spread":"NA","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 3 day 1, predose"},{"categories":[{"measurements":[{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG000","spread":"NA","value":"111"},{"groupId":"OG001","spread":"303","value":"175"},{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG002","spread":"NA","value":"178"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 3 day 1, 1 - 2.5 hours post EOI"},{"categories":[{"measurements":[{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG000","spread":"NA","value":"2.00"},{"groupId":"OG001","spread":"323","value":"255"},{"comment":"Standard deviation not calculated when N ≤ 2","groupId":"OG002","spread":"NA","value":"69.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Cycle 3 day 1, 2.75 - 5 hours post EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Plasma samples for oprozomib concentration assays were only collected for participants in the 5/14 dosing schedule groups.\n\nOprozomib plasma concentrations were determined using liquid chromatography with tandem mass spectrometry.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first.\n\nAfter completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.","id":"OG000","title":"Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone"},{"description":"Participants received oprozomib 180 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first.\n\nAfter completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.","id":"OG001","title":"Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone"},{"description":"Participants received oprozomib 210 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first.","id":"OG002","title":"Oprozomib 210 mg 5/14 + Lenalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"Participants in the 5/14 dosing schedule groups with available concentration data","reportingStatus":"POSTED","timeFrame":"Cycle 1 day 1 at 1 to 2.5 hours and 2.75 to 5 hours after end of infusion (EOI) and cycle 3 day 1 at predose and 1 to 2.5 hours and 2.75 to 5 hours after EOI.","title":"Plasma Oprozomib Concentration","type":"SECONDARY","unitOfMeasure":"ng/mL"}